ClinicalTrials.gg
Not yet recruitingNCT07363408Updated Sep 2, 2026

Ivonescimab and ADG126, Alone, and in Combination With Leucovorin and Fluorouracil or FOLFIRI Regimen for the Treatment of Microsatellite Stable Advanced/Metastatic Colorectal Cancer

A Phase 1 interventional study of Biospecimen Collection and Computed Tomography in Advanced Microsatellite Stable Colorectal Carcinoma, Metastatic Microsatellite Stable Colorectal Carcinoma and Stage III Colorectal Cancer AJCC v8, sponsored by City of Hope Medical Center. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-02.

Sponsored by City of Hope Medical Center · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 42 studies in Colorectal Neoplasms by City of Hope Medical Center — 17 open to participants now, 22 under way, 2 of them phase 3. Colorectal Neoplasms · City of Hope Medical Center.

Planned enrollment
14th of 28
30 · median 30
Started
2026
with 2 others
Phase 1
11 of 42
4 open now
Primary completion
2027-07
later than 5 of 21 live
Registered
40th of 42
by date

Among the 42 studies in Colorectal Neoplasms by City of Hope Medical Center, this one is the 14th largest by planned enrollment of the 28 interventional ones that give a count, is one of 3 that started in 2026, is one of 11 in phase 1, reaches primary completion later than 5 of the 21 other live ones, and was the 40th registered.

Colorectal Neoplasms

6,556 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

17 of the 42 studies in Colorectal Neoplasms by City of Hope Medical Center are open now, in 5 countries. Recruiting first, the newest first:

11 more — sign in →

By country, each count listing its studies:

All 17 open studies →

Where they have run

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 42 studies in Colorectal Neoplasms by City of Hope Medical Center, or all of them as a file.
02

Study summary

This phase I trial studies the safety, side effects, and best dose of ADG126, in combination with ivonescimab alone, in combination with ivonescimab, leucovorin, and fluorouracil, or in combination with ivonescimab and leucovorin, fluorouracil, and irinotecan (FOLFIRI regimen) in treating patients with microsatellite stable (MSS) colorectal cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) or has spread from where it first started (primary site) to other places in the body (metastatic). Immunotherapy with monoclonal antibodies, such as ivonescimab and ADG126, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Ivonescimab may also stop or slow the cancer by blocking the growth of new blood vessels necessary for tumor growth. Leucovorin calcium is a type of drug called a folic acid analog, which means it is similar to the vitamin folic acid. It is used in combination with certain chemotherapy drugs to enhance their ability to kill tumor cells or to lessen their harmful side effects. Fluorouracil is a type of chemotherapy called an antimetabolite, which is a drug that mimics a natural chemical and prevents its use in cells. It interferes with the production of a key component of deoxyribonucleic acid (DNA), which prevents the DNA from copying itself. This causes tumor cells and other rapidly dividing cells to die. Fluorouracil also gets incorporated into ribonucleic acid (RNA) and DNA, disrupting critical cell functions. Irinotecan is in a class of antineoplastic medications called topoisomerase I inhibitors. It blocks a certain enzyme needed for cell division and DNA repair and may kill cancer cells. Giving ADG126 with ivonescimab, with or without leucovorin and fluorouracil or FOLFIRI regimen, may be safe in treating patients with MSS advanced/metastatic colorectal cancer.

Read the detailed description

PRIMARY OBJECTIVES:

I. Determine the recommended phase II dose of muzastotug (ADG126) and ivonescimab (Arm A) in advanced/metastatic MSS colorectal cancer without liver metastatic disease.

II. Determine the recommended phase II dose of ADG126 and ivonescimab with fluorouracil (5-FU)/leucovorin (LV) (Arm B) in advanced/metastatic MSS colorectal cancer.

III. Determine the recommended phase II dose of ADG126 and ivonescimab with leucovorin, fluorouracil, and irinotecan (FOLFIRI) (Arm C) in advanced/metastatic MSS colorectal cancer.

SECONDARY OBJECTIVES:

I. Describe the safety of giving ADG126 with ivonescimab, and in combination with 5-FU/LV, and in combination with FOLFIRI in MSS advanced/metastatic colorectal cancer.

II. Describe the overall response rate (ORR) as evaluated by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 for the three treatment arms individually.

III. Describe the duration of response (DoR), progression free survival (PFS), and overall survival (OS) of each of the three treatment arms.

IV. Assess ADG126 pharmacokinetics (PK) through sparse sampling at different doses of ADG126 on study and in combination with ivonescimab, 5-FU/LV, or FOLFIRI.

EXPLORATORY OBJECTIVE:

I. Explore the dynamics of immune cells in relation to clinical outcome by treatment arm, which include the data from immunophenotyping, cytokine analysis and ribonucleic acid (RNA) sequencing of peripheral blood and buffy coat at baseline, 4 weeks, and 8 weeks, and every subsequent 8 weeks until progression.

OUTLINE: This is a dose-escalation study of muzastotug in combination with ivonescimab, leucovorin, fluorouracil, and irinotecan. Patients are assigned to 1 of 3 arms.

ARM A: Patients receive muzastotug intravenously (IV) over 60-90 minutes on day 1 of each cycle and ivonescimab IV over 60 minutes on days 1, 15, and 29 of each cycle. Cycles repeat every 6 weeks for up to 24 months in the absence of disease progression or unacceptable toxicity. Patients also undergo computed tomography (CT) or magnetic resonance imaging (MRI), and collection of blood samples throughout the study.

ARM B: Patients receive muzastotug IV over 60-90 minutes on day 1 of each cycle, ivonescimab IV over 60 minutes on days 1, 15, and 29 of each cycle, leucovorin IV over 2 hours on days 1, 15, and 29 of each cycle, and fluorouracil IV continuously over 46 hours on days 1, 15, and 29 of each cycle. Cycles repeat every 6 weeks for up to 24 months in the absence of disease progression or unacceptable toxicity. Patients also undergo CT or MRI, and collection of blood samples throughout the study.

ARM C: Patients receive muzastotug IV over 60-90 minutes on day 1 of each cycle, ivonescimab IV over 60 minutes on days 1, 15, and 29 of each cycle, leucovorin IV over 2 hours on days 1, 15, and 29 of each cycle, fluorouracil IV continuously over 46 hours on days 1, 15, and 29 of each cycle, and irinotecan IV over 90 minutes on day 1 of each cycle. Cycles repeat every 6 weeks for up to 24 months in the absence of disease progression or unacceptable toxicity. Patients also undergo CT or MRI, and collection of blood samples throughout the study.

After completion of study treatment, patients are followed for 30 days, every 3 months until disease progression (if applicable) for 2 years and/or after disease progression periodically for survival.

03

Conditions studied

  • Advanced Microsatellite Stable Colorectal Carcinoma
  • Metastatic Microsatellite Stable Colorectal Carcinoma
  • Stage III Colorectal Cancer AJCC v8
  • Stage IV Colorectal Cancer AJCC v8
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Documented of the participant and/or legally authorized representative
  • Agreement to blood collection for correlative analysis at baseline, 4 weeks, and 8 weeks, and then every subsequent 8 weeks
  • Age: ≥ 18 years
  • (ECOG) ≤ 1
  • confirmed advanced/ MSS colorectal cancer. MSS status must have been confirmed by a Clinical Laboratory Improvement Amendments (CLIA) certified assay
  • by 1.1
  • Fully recovered from the acute, , toxic effects (except alopecia) to ≤ grade 1 to prior anti-cancer therapy
  • ARM A ONLY: Patients should not have evidence of hepatic metastatic disease
  • ARM A ONLY: Patients should have progressed following irinotecan, oxaliplatin, fluoropyrimidine, and an anti-EGFR if clinically indicated
  • ARM B ONLY: Patient is eligible for maintenance 5-FU/LV or 5-FU/LV bevacizumab
  • ARM B ONLY: No history of significant toxicity to 5-FU/LV that required dose reduction in infusional 5-FU dosing
  • ARM C ONLY: Patient is eligible for FOLFIRI chemotherapy
  • ARM C ONLY: No history of significant toxicity to 5-FU/LV or irinotecan that required dose reduction in infusional 5-FU dosing or irinotecan
  • ARM C ONLY: No prior progression on prior irinotecan and no prior dose reduction on irinotecan due to toxicity
  • (ANC) ≥ 1.5 × 10\^9/L

    • NOTE: no blood transfusions or growth factor therapy used within 7 days of the screening complete blood count (CBC)
  • ≥ 100 × 10\^9/L

    • NOTE: no blood transfusions or growth factor therapy used within 7 days of the screening CBC
  • ≥ 9.0 g/dL

    • NOTE: no blood transfusions or growth factor therapy used within 7 days of the screening CBC
  • Serum total (TBIL) ≤ 1.5 × (ULN); For patients with liver metastases or confirmed/suspected Gilbert syndrome, TBIL ≤ 3 × ULN
  • (AST) ≤ 2.5 x ULN; For patients with liver metastases ≤ 5 x ULN
  • Alanine aminotransferase (ALT) ≤ 2.5 x ULN; For patients with liver metastases ≤ 5 x ULN
  • of ≥ 50 mL/min per 24 hour urine test or the Cockcroft-Gault formula or estimated (eGFR) value ≥ 30 mL/min using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation (adjustment by body surface area [BSA] is not required for eGFR; eGFR can be determined using the calculator from the National Kidney Foundation website [www.kidney.org])
  • (INR) OR prothrombin (PT) ≤ 1.5 x ULN (unless abnormalities are unrelated to coagulopathy). This applies only to patients who are not on therapeutic anti-coagulation. Patients receiving therapeutic anti-coagulation should be on a stable dose
  • Urine protein \< 2+ or 24-hour urine protein quantification \< 1.0 g
  • For patients with KNOWN history of , virus (HCV) and/or virus (HBV) seropositivity only, nucleic acid quantitation for their virus must be performed.

    • HIV-infected patients on effective anti-retroviral therapy with undetectable viral load and a cd4 > 400 are eligible for this trial.
    • Patients with known active hepatitis B are required to have hepatitis B DNA \< 200 IU/ml by polymerase chain reaction (PCR) and on appropriate anti-viral therapy with acceptable tolerability for one month prior to randomization.
    • All patients with known active hepatitis C (hepatitis C virus [HCV] antibody positive with HCV RNA levels above the lower limit of detection) are excluded
  • Women of (WOCBP): negative urine or serum pregnancy test

    • If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.
  • Female patient of childbearing potential having sex with an unsterilized male partner must agree to use a highly effective method of from the beginning of screening until 6 months after the last dose of study drug. Unsterilized male patients having sex with a female partner of childbearing potential, or a pregnant or breastfeeding partner must agree to use barrier contraception (male condom) for the duration of the treatment period until 6 months after the last dose of study drug. Male patients with female partners of childbearing potential must have the female partner agree to use at least 1 form of highly effective contraception for the duration of the treatment period until 6 months after the last dose of study drug

    • Childbearing potential defined as not being surgically sterilized (men and women) or have not been free from menses for > 1 year (women only)

Exclusion criteria

Exclusion Criteria:

  • Major surgical procedures or serious trauma within 4 weeks prior to study entry, or plans for major surgical procedures within 4 weeks after the first dose (as determined by the investigator). Minor local procedures (excluding central venous catheterization and port implantation) within 3 days prior to study entry
  • Known history of allogeneic organ transplantation or hematopoietic stem cell transplantation
  • Chemotherapy, radiation therapy, biological therapy, immunotherapy within 21 days or five half-lives (whichever is shorter for non-radiation therapy) prior to day 1 of protocol therapy
  • Strong inducers/ inhibitors within 14 days prior to day 1 of protocol therapy (Arm C only)
  • UGT1A1 inhibitors within 14 days prior to day 1 of protocol therapy (Arm C only)
  • Any other anti-cancer therapy is prohibited, including but not limited to antibody-based therapy, retinoids, nitrosourea therapy, mitomycin C, small molecule tyrosine kinase inhibitors, proprietary Chinese medicines with anti-cancer activity, or radiotherapy
  • Herbal medications must be cleared by the principal investigator (PI)
  • Prior exposure to or PD-L1 or CTLA-4 targeting agents
  • History of bleeding tendencies or coagulopathy and/or bleeding symptoms or risk within 4 weeks prior to study entry, including but not limited to:

    • Hemoptysis (defined as coughing up ≥ 0.5 teaspoon of fresh blood or small blood clots) Note: transient hemoptysis associated with diagnostic bronchoscopy is allowed
    • Nasal bleeding/epistaxis (bloody nasal discharge is allowed)
    • Current use of prophylactic or full-dose anticoagulants or anti- agents for therapeutic purposes that is not stable prior to study entry is not allowed. The use of full-dose anticoagulants is permitted as long as the (INR) or activated partial thromboplastin time (aPTT) is within therapeutic limits according to the medical standard of the enrolling institution or with the use of factor Xa inhibitors
  • Poorly controlled hypertension with repeated systolic blood pressure ≥ 150 mmHg or diastolic blood pressure ≥ 100 mmHg after oral antihypertensive therapy
  • Active or lung disease requiring systemic therapy (eg, with disease modifying drugs, prednisone > 10 mg daily or equivalent, therapy) within 2 years prior to study entry, however the following will be allowed:

    • Replacement therapy (eg, thyroxine, insulin, or physiologic replacement therapy for adrenal or pituitary insufficiency) is permitted.
    • Intermittent use of bronchodilators, inhaled corticosteroids, or local corticosteroid injections is permitted
  • History of major diseases before study entry, specifically:

    • Unstable angina, myocardial infarction, congestive heart failure ( [NYHA] classification ≥ grade 2) or unstable vascular disease (eg, aortic aneurysm at risk of rupture, Moyamoya disease) that required hospitalization within 12 months prior to study entry, or other cardiac impairment that may affect the safety evaluation of the study drug (eg, poorly controlled arrhythmias, myocardial ischemia)
    • History of esophageal gastric varices, severe ulcers, wounds that do not heal, abdominal fistula, intra-abdominal abscesses, or acute gastrointestinal bleeding within 6 months before study entry
    • History of any grade arterial thromboembolic event, grade 3 and above venous thromboembolic event, as specified in National Cancer Institute (NCI) (CTCAE) 5.0, , cerebrovascular accident, hypertensive crisis, or hypertensive encephalopathy within 12 months prior to study entry
    • Acute exacerbation of within 4 weeks before study entry
    • History of perforation of the gastrointestinal tract and/or fistula, history of gastrointestinal obstruction (including incomplete intestinal obstruction requiring parenteral nutrition), extensive bowel resection (partial colectomy or extensive small bowel resection) within 6 months prior to study entry
  • Imaging during the screening period shows that the patient has:

    • Radiologically documented evidence of major blood vessel invasion or fistula
  • Symptomatic central nervous system (CNS) , with hemorrhagic features, CNS metastasis ≥ 1.5 cm, CNS radiation within 7 days prior to study entry, potential need for CNS radiation within the first cycle, or . Note: Patients must have stopped corticosteroids or be on physiologic corticosteroid replacement therapy (prednisone ≤ 10 mg daily or equivalent)
  • or live attenuated vaccine within 4 weeks prior to planned study entry, or if scheduled to receive a live vaccine or live attenuated vaccine during the study period. Inactivated vaccines are permitted
  • Severe infection within 4 weeks prior to study entry, including but not limited to comorbidities requiring hospitalization, sepsis, or severe pneumonia; active infection (as determined by the investigator) requiring systemic anti-infective therapy within 2 weeks prior to study entry, (excluding antiviral therapy for or C)
  • Has pre-existing peripheral neuropathy that is ≥ grade 2 by CTCAE version 5.0
  • Uncontrolled pleural effusions, pericardial effusions, or ascites that is clinically symptomatic or required paracentesis in the last 4 weeks prior to enrollment
  • History of non-infectious pneumonia requiring systemic corticosteroids, or current interstitial lung disease
  • Active or prior history of inflammatory bowel disease (eg, Crohn's disease, ulcerative colitis, or chronic diarrhea)
  • Current use of systemic corticosteroids (>10 mg daily prednisone or equivalent)
  • High risk for bowel perforation such as obstructive gastrointestinal (GI) findings on imaging or symptoms suggesting bowel obstruction (post-prandial cramping, nausea, or vomiting)
  • Presence of an enteric stent
  • Open non-healing wounds
  • History of bowel perforation unless related to the primary tumor and unless the tumor was resected or the patient has been diverted proximal to the tumor
  • Known allergy to any component of any study drug; known history of severe to other monoclonal antibodies; history of allergic reactions attributed to compounds of similar chemical or biologic composition to any study agent
  • History or current evidence of any condition (medical [including adverse events from prior anticancer therapy, disorders secondary to tumor], surgical or psychiatric [including substance abuse]), or laboratory abnormality that might confound the results of the study, interfere with the patient's participation for the full duration of the study, might lead to higher medical risk and/or is not in the best interest of the patient to participate, in the opinion of the treating investigator
  • Clinically significant uncontrolled illness
  • Other active . Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the regimen are eligible for this trial
  • Patient is breastfeeding or plans to breastfeed during the study
  • Females only: Pregnant
  • Any other condition that would, in the investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns with clinical study procedures
  • Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics)
Terms in these criteria, in plain language(37)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Arm A (muzastotug, ivonescimab)

    Patients receive muzastotug IV over 60-90 minutes on day 1 of each cycle and ivonescimab IV over 60 minutes on days 1, 15, and 29 of each cycle. Cycles repeat every 6 weeks for up to 24 months in the absence of disease progression or unacceptable toxicity. Patients also undergo CT or MRI, and collection of blood samples throughout the study.

    Procedure: Biospecimen Collection · Procedure: Computed Tomography · Biological: Ivonescimab · Procedure: Magnetic Resonance Imaging · Biological: Muzastotug

  • Experimental
    Arm B (muzastotug, ivonescimab, leucovorin, fluorouracil)

    Patients receive muzastotug IV over 60-90 minutes on day 1 of each cycle, ivonescimab IV over 60 minutes on days 1, 15, and 29 of each cycle, leucovorin IV over 2 hours on days 1, 15, and 29 of each cycle, and fluorouracil IV continuously over 46 hours on days 1, 15, and 29 of each cycle. Cycles repeat every 6 weeks for up to 24 months in the absence of disease progression or unacceptable toxicity. Patients also undergo CT or MRI, and collection of blood samples throughout the study.

    Procedure: Biospecimen Collection · Procedure: Computed Tomography · Drug: Fluorouracil · Biological: Ivonescimab · Drug: Leucovorin Calcium · Procedure: Magnetic Resonance Imaging · Biological: Muzastotug

  • Experimental
    Arm C (muzastotug, ivonescimab, FOLFIRI)

    Patients receive muzastotug IV over 60-90 minutes on day 1 of each cycle, ivonescimab IV over 60 minutes on days 1, 15, and 29 of each cycle, leucovorin IV over 2 hours on days 1, 15, and 29 of each cycle, fluorouracil IV continuously over 46 hours on days 1, 15, and 29 of each cycle, and irinotecan IV over 90 minutes on day 1 of each cycle. Cycles repeat every 6 weeks for up to 24 months in the absence of disease progression or unacceptable toxicity. Patients also undergo CT or MRI, and collection of blood samples throughout the study.

    Procedure: Biospecimen Collection · Procedure: Computed Tomography · Drug: Fluorouracil · Drug: Irinotecan · Biological: Ivonescimab · Drug: Leucovorin Calcium · Procedure: Magnetic Resonance Imaging · Biological: Muzastotug

Interventions

  • ProcedureBiospecimen Collection

    Undergo blood sample collection

    Also known as: Biological Sample Collection, Biospecimen Collected, Specimen Collection

  • ProcedureComputed Tomography

    Undergo CT

    Also known as: CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, Diagnostic CAT Scan, Diagnostic CAT Scan Service Type, tomography

  • Given IV

    Also known as: 5 Fluorouracil, 5 Fluorouracilum, 5 FU, 5-Fluoro-2,4(1H, 3H)-pyrimidinedione, 5-Fluorouracil, 5-Fluracil, 5-Fu, 5FU, AccuSite, Carac, Fluoro Uracil, Fluouracil, Flurablastin, Fluracedyl, Fluracil, Fluril, Fluroblastin, Ribofluor, Ro 2-9757, Ro-2-9757

  • Given IV

  • BiologicalIvonescimab

    Given IV

    Also known as: AK 112, AK-112, AK112, Anti-PD-1/Anti-VEGF Bispecific Antibody AK112, Anti-PD-1/VEGF Bispecific Antibody AK112, PD-1/VEGF Bispecific Antibody AK112, SMT 112, SMT-112, SMT112

  • DrugLeucovorinStudies of LeucovorinLeucovorin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Given IV

    Also known as: Adinepar, Calcifolin, Calcium (6S)-Folinate, Calcium Folinate, Calcium Leucovorin, Calfolex, Calinat, Cehafolin, Citofolin, Citrec, Citrovorum Factor, Cromatonbic Folinico, Dalisol, Disintox, Divical, Ecofol, Emovis, Factor, Citrovorum, Flynoken A, Folaren, Folaxin, FOLI-cell, Foliben, Folidan, Folidar, Folinac, Folinate Calcium, folinic acid, Folinic Acid Calcium Salt Pentahydrate, Folinoral, Folinvit, Foliplus, Folix, Imo, Lederfolat, Lederfolin, Leucosar, leucovorin, Rescufolin, Rescuvolin, Tonofolin, Wellcovorin

  • ProcedureMagnetic Resonance Imaging

    Undergo MRI

    Also known as: Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI

  • BiologicalMuzastotug

    Given IV

    Also known as: ADG 126, ADG-126, ADG126, Anti-CTLA-4 Monoclonal Antibody ADG126, Anti-CTLA-4 SAFEbody ADG126

06

What researchers measure

Primary outcomes

  1. Incidence of dose limiting toxicities

    Will be assessed by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0, by treatment arm. Descriptive statistics will be used for all safety, efficacy and immunogenicity parameters. Data will be summarized using descriptive statistics (number of subjects, mean, median, standard deviation, minimum, and maximum) for continuous variables and using frequencies and percentages for categorical variables. Differences among groups will be tested using the Fisher's exact test and Kruskal-Wallis test for categorical and continuous variables, respectively.

    Time frame: Up to 6 weeks or 3 doses of ivonescimab, whichever is longer

Secondary outcomes

  1. Treatment-related adverse event rates

    Will be assessed by NCI CTCAE version 5.0, delineated by grade and attribution, by treatment arm. Descriptive statistics will be used for all safety, efficacy and immunogenicity parameters. Data will be summarized using descriptive statistics (number of subjects, mean, median, standard deviation, minimum, and maximum) for continuous variables and using frequencies and percentages for categorical variables. Differences among groups will be tested using the Fisher's exact test and Kruskal-Wallis test for categorical and continuous variables, respectively.

    Time frame: Up to 30 days after completion of study treatment

  2. Objective response rate

    Defined as rate of participants achieving confirmed complete response (CR) or partial response (PR), as assessed by the investigator using Response Evaluation Criteria in Solid Tumors 1.1. The point estimate and 95% confidence intervals will be provided using the Clopper-Pearson methods. Logistic regression modeling of responders (CR or PR) and non-responders will be used to estimate the level of association of treatment and objective response.

    Time frame: From the start of the study treatment and disease progression or death due to any cause prior to receiving another therapy, whichever occurs first, assessed up to 2 years after completion of study treatment

  3. Duration of response

    Survival distributions will be estimated using the Kaplan-Meier (KM) method. Survival curves will be compared between groups using the log-rank test. Median and landmark time-point estimates will be based on the KM estimates. The average hazard ratios (HR) will be estimated using a Cox proportional-hazards model. An assessment of the proportional-hazards assumption will be performed, and an assessment of the time-dependent HR will be done.

    Time frame: From the time when a response is experienced to progression or death, assessed up to 2 years after completion of study treatment

  4. Progression-free survival

    Survival distributions will be estimated using the KM method. Survival curves will be compared between groups using the log-rank test. Median and landmark time-point estimates will be based on the KM estimates. The average HR will be estimated using a Cox proportional-hazards model. An assessment of the proportional-hazards assumption will be performed, and an assessment of the time-dependent HR will be done.

    Time frame: From the start of treatment to disease progression or death from any cause, whichever occurs first, assessed up to 2 years after completion of study treatment

  5. Overall survival

    Survival distributions will be estimated using the KM method. Survival curves will be compared between groups using the log-rank test. Median and landmark time-point estimates will be based on the KM estimates. The average HR will be estimated using a Cox proportional-hazards model. An assessment of the proportional-hazards assumption will be performed, and an assessment of the time-dependent HR will be done.

    Time frame: From start of treatment to death due to any cause, assessed up to 2 years after completion of study treatment

  6. Plasma concentrations of cleaved and intact ADG126

    Changes over time in the levels of biomarkers will be measured using Wilcoxon signed rank test and linear mixed effect model.

    Time frame: Up to 30 days after completion of study treatment

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Jul 2027, 7 months later.

Of 166 non-industry phase 1 interventional studies under Colorectal Neoplasms, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 74. This study's planned 7 months is below that.

Counting every sponsor, half of 435 studies reached it within 48 months; a quarter within 31 and three quarters within 70.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 22, 2026
First posted
Jan 23, 2026
StartEst.
Dec 1, 2026
Primary completionEst.
Jul 21, 2027
CompletionEst.
Jul 21, 2027
Last update
Sep 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07363408
Responsible party
Sponsor
First posted
Jan 23, 2026
Start date
Dec 1, 2026 (estimated)
Primary completion
Jul 21, 2027 (estimated)
Completion
Jul 21, 2027 (estimated)
Last update
Sep 2, 2026

Study contacts

Marwan G Fakih
principal investigator · City of Hope Medical Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ivonescimab · Muzastotug

Start the discussion